Extracellular matrix proteins in epiretinal membranes and in diabetic retinopathy

Current Eye Research

Volumn 34, Issue 2, 2009, Pages 134-144

  George, Biju ^a   Chen, Shali ^a   Chaudhary, Varun ^a   Gonder, John ^a   Chakrabarti, Subrata ^a,b  

^a WESTERN UNIVERSITY   (Canada)

^b DSB   (Canada)

Author keywords

Diabetes; Epiretinal membrane; Fibronectin; Prolifearative diabetic retinopathy; Transforming growth factor

Indexed keywords

BIOLOGICAL MARKER; COLLAGEN TYPE 1; ENDOTHELIN 1; FIBRONECTIN; MESSENGER RNA; SCLEROPROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC RETINOPATHY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIRETINAL MEMBRANE; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROLIFERATIVE RETINOPATHY; PROTEIN BLOOD LEVEL; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; VASCULAR TISSUE; VISUAL IMPAIRMENT; VITRECTOMY; VITREOUS BODY;

AGED; DIABETIC RETINOPATHY; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPIRETINAL MEMBRANE; EXTRACELLULAR MATRIX PROTEINS; FEMALE; GENE EXPRESSION REGULATION; HUMANS; MALE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; UP-REGULATION; VITREOUS BODY;

EID: 60749115085     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.1080/02713680802585946     Document Type: Article

References (50)

1. Mitchell P, Smith W, Chey T, Wang JJ, Chang A. Prevalence and associations of epiretinal membranes. The Blue Mountains Eye Study, Australia. Ophthalmology 1997;104:1033-1040.
2. Tadayoni R, Paques M, Massin P, Mouki-Benani S, Mikol J, Gaudric A. Dissociated optic nerve fiber layer appearance of the fundus after idiopathic epiretinal membrane removal. Ophthalmology 2001;108:2279-2283.
3. Fraser-Bell S, Guzowski M, Rochtchina E, Wang JJ, Mitchell P. Five-year cumulative incidence and progression of epiretinal membranes: The Blue Mountains Eye Study. Ophthalmology 2003;110:34-40.
4. Miller B. Epiretinal macular membranes: Pathogenesis and treatment. Dev Ophthalmol 1997;29:61-63.
5. Machemer R, Laqua H. Pigment epithelial proliferation in retinal detachment (massive periretinal proliferation). Am J Ophthalmol 1975;80:1-23.
6. Machemer R. Pathogenesis and classification of massive periretinal proliferation. Br J Ophthalmol 1978;62:737-747.
7. Habib MS, Steel DH, Ling R, James C, Fetherston TJ, McLeod D, Inglesby DV. Vitrectomy with membrane peeling for vasocentric idiopathic epiretinal membranes. Retina 2008;28:981-986.
8. Hiscott P, Morino I, Alexander R, Grierson I, Gregor Z. Cellular components of subretinal membranes in proliferative vitreoretinopathy. Eye 1989;3:606-610.
9. Hiscott P, Gray R, Grierson I, Gregor Z. Cytokeratin containing cells in proliferative diabetic retinopathy membranes. Br J Ophthalmol 1994;78:219-222.
10. Caird FI. The epidemiology of diabetic microangiopathy. Acta Diabetol Lat 1971;8:240-248.
11. Mazze RS, Sinnock P, Deeb L, Brimberry JL. An epidemiological model for diabetes mellitus in the United States: Five major complications. Diabet Res Clin Pract 1985;1:185-191.
12. King GL, Brownlee M. The cellular and molecular mechanisms of diabetic complications. Endocrinol Metab Clin N Am 1996;25:255-270.
13. Khan ZA, Chan BM, Uniyal S, Barbin YP, Farhangkhoee H, Chen S, Chakrabarti S. EDB FN and angiogenesis - A novel mechanistic pathway. Angiogenesis 8:183-196, 2005.
14. McLeod D. The vitreous and its disorders. In: Miller S (ed). Clinical Ophthalmology. Bristol, UK: Wright; 1987, pp. 258-274.
15. Hiscott PS, Grierson I, McLeod D. The natural history of epiretinal membranes: A quantitative, immunohistochemical, and autoradiographic study. Br J Ophthalmol 1985;69:810-823.
16. Rodrigues MM, Newsome DA, Machemer R. Further characterization of epiretinal membranes in human massive periretinal proliferation. Curr Eye Res 1981;1:311-315.
17. Weller M, Weidemann P, Bresgen M, Heimann K. Vitronectin and proliferative intraocular disorders. I. A colocalisation study of the serum spreading factor, vitronectin, and FN in traction membranes from patients with proliferative vitreoretinopathy. Int Ophthalmol 1991;15:93-101.
18. Koya D, King GL. Protein kinase C activation and the development of diabetic complications. Diabetes 1998;47:859-866.
19. Ljubimov AV, Burgeson RE, Butkowski RJ, et al. Basement membrane abnormalities in human eyes with diabetic retinopathy. J Histochem Cytochem 1996;44:1469-1479.
20. Evans T, Deng DX, Chakrabarti S. Endothelin receptor blockade prevents augmented extracellular matrix protein component mRNA expression and capillary basement membrane thickening in the retina of diabetic and galactose fed rats. Diabetes 2000;49:662-666.
21. Roy S, Cagliero E, Lorenzi M. FN overexpression in retinal microvessels of patients with diabetes. Invest Ophthalmol Vis Sci 1996;37:258-266.
22. Yamada KM. Cell surface interactions with extracellular materials. Annu Rev Biochem 1983;52:761-799.
23. Kornblihtt AR, Umezawa K, Vibe-Pedersen K, Baralle FE. Primary structure of human FN:Differential splicingmay generate at least 10 polypeptides from a single gene.EMBO J 1996;4:1755-1759.
24. Jaffe EA, Mosher DF. Synthesis of FN by cultured human endothelial cells. Ann NY Acad Sci 1978;312:122-131.
25. Gutman A, Kornblihtt AR. Identification of a third region of cell specific alternative splicing in human FN mRNA. Proc Natl Acad Sci USA 1987;84:7179-7182.
26. Norton PA, Hynes RO. Alternative splicing of chicken FN in embryos and in normal and transformed cells. Mol Cell Biol 1987;7:4297-4307.
27. Oyama F, Hirohashi S, Shimosato Y, Titani K, Sekiguchi K. Deregulation of alternative splicing of FN pre-mRNA in malignant human liver tissues. J Biol Chem 1989;264:10331-10334.
28. Colombi M, Barlati S, Kornblihtt A, Baralle FE, Vaheri A. A family of FN mRNAs in human normal and transformed cells. Biochem Biophys Acta 1986;868:207-214.
29. Demartis S, Tarli L, Borsi L, Zardi L, Neri D. Selective targeting of tumour neovasculature by a radiohalogenated human antibody fragment specific for the ED-B domain of FN. Eur J Nucl Med 2001;28:534-539.
30. Castellani P, Dorcaratto A, Pau A, et al. The angiogenesis marker ED-B FN isoform in intracranial meningiomas. Acta Neurochir 2000;142:277-282.
31. Nickeleit V, Kaufman AH, Zagachin L, Dutt JE, Foster CS, Colvin RB. Healing corneas express embryonic FN isoforms in the epithelium, subepithelial stroma, and endothelium. Am J Pathol 1996;149:549-558.
32. Borsi L, Castellani A, Risso AM, Leprini A, Zardi L. Transforming growth factor-β regulates the splicing pattern of FN messenger RNA precursor. FEBS Lett 1990;261:175-178.
33. Balza E, Borsi L, Allemanni G, Zardi L. Transforming growth factor regulates the level of different FN isoforms in normal human cultured fibroblasts. FEBS Lett 1998;228:42-44.
34. Shankland SJ, Scholey JW. Expression of transforming growth factor 1 during diabetic renal hypertrophy. Kidney Int 1994;42:430-442.
35. Chen S, Evans T, Deng D, Cukiernik M, Chakrabarti S. Hyperhexosemia- induced functional and structural changes in the kidneys: Role of endothelins. Nephron 2002;90:86-94.
36. Chen S, Mukherjee S, Chakraborty C, Chakrabarti S. High glucose induced, endothelin-dependent FN synthesis is mediated via NF-kappa B and AP-1. Am J Physiol 2003;284:C263-C272.
37. Deng D, Evans T, Mukherjee K, Downey D, Chakrabarti S. Diabetes-induced vascular dysfunction in the retina: Role of endothelins. Diabetologia 1999;42:1228-1234.
38. Khan ZA, Barbin YP, Farhangkhoee H, Beier N, Scholz W, Chakrabarti S. Glucose-induced serum- and glucocorticoid-regulated kinase activation in oncofetal FN expression. Biochem Biophys Res Commun 2005;329:275-280.
39. Chen S, Khan ZA, Cukiernik M, Chakrabarti S. Differential activation of NF-kappa B and AP-1 in increased FN synthesis in target organs of diabetic complications. Am J Physiol Endocrinol Metab 2003;284:E1089-E1097.
40. Khan ZA, Farhangkhoee H, Mahon JL, Bere L, Gonder JR, Chan BM, Uniyal S, Chakrabarti S. Endothelins: Regulators of extracellular matrix protein production in diabetes. Exp Biol Med (Maywood) 2006;231:1022-1029.
41. Xin X, Chen S, Khan ZA, Chakrabarti S. Akt activation and augmented FN production in hyperhexosemia. Am J Physiol Endocrinol Metab 2007;293:E1036-1044.
42. Campochiaro PA, Jerdan JA, Glaser BM. Serum contains chemoattractants for human retinal pigment epithelial cells. Arch Ophthalmol 1984;102:1830-1833.
43. Campochiaro PA, Jerdan JA, Glaser BM, Cardin AC, Michels, RG. Vitreous aspirates from patients with proliferative vitreoretinopathy stimulate retinal pigment epithelial cell migration. Arch Ophthalmol 1985;103:1403-1405.
44. Allamby D, Foreman D, Carrington L, McLeod D, Boulton M. Cell attachment to, and contraction of, the retina in vitro. Invest Ophthalmol Vis Sci 1997;38:2064-2072.
45. Heling A, Zimmermann R, Kostin S, Maeno Y, Hein S, Devaux B et al. Increased expression of cytoskeletal, linkage, and extracellular proteins in failing human myocardium. Circ Res 2000;86(8):846-853.
46. Ogawa E, Saito Y, Harada M, Kamitani S, Kuwahara K, Miyamoto Y et al. Outside-in signalling of FN stimulates cardiomyocyte hypertrophy in cultured neonatal rat ventricular myocytes. J Mol Cell Cardiol 2000;32:765-776.
47. Minchiotti S, Stampachiacchiere B, Micera A, Lambiase A, Ripandelli G, Billi B, Bonini S. Human idiopathic epiretinal membranes express NGF and NGF receptors. Retina 2008;28:628-637.
48. Roldán-Pallarés M, Rollín R, Martínez-Montero JC, Fernández-Cruz A, Bravo-Llata C, Fernández-Durango R. Immunoreactive endothelin-1 in the vitreous humor and epiretinal membranes of patientswith proliferative diabetic retinopathy. Retina 2007;27:222-235.
49. Harada C, Harada T, Mitamura Y, Quah HM, Ohtsuka K, Kotake S, Ohno S, Wada K, Takeuchi S, Tanaka K. Diverse NF-κB expression in epiretinal membranes after human diabetic retinopathy and proliferative vitreoretinopathy. Mol Vis 2004;10:31-36.
50. Locci P, Balducci C, Lilli C, Marinucci L, Becchetti E, Dolci C, Calastrini C, Lumare E, Stabellini G. Desmoid and fibroma tumors differently respond to TGFbeta(1) stimulus and ECM macromolecule accumulation. Biomed Pharmacother 2007;61:131-136.